PTI vs. SPRB, DRRX, CASI, DARE, ENLV, JAN, APRE, THTX, FBIO, and VIRX
Should you be buying Proteostasis Therapeutics stock or one of its competitors? The main competitors of Proteostasis Therapeutics include Spruce Biosciences (SPRB), DURECT (DRRX), CASI Pharmaceuticals (CASI), Daré Bioscience (DARE), Enlivex Therapeutics (ENLV), JanOne (JAN), Aprea Therapeutics (APRE), Theratechnologies (THTX), Fortress Biotech (FBIO), and Viracta Therapeutics (VIRX). These companies are all part of the "medical" sector.
Proteostasis Therapeutics (NASDAQ:PTI) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking.
In the previous week, Spruce Biosciences had 2 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 2 mentions for Spruce Biosciences and 0 mentions for Proteostasis Therapeutics. Spruce Biosciences' average media sentiment score of 0.64 beat Proteostasis Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.
Proteostasis Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500.
Proteostasis Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -474.96%. Spruce Biosciences' return on equity of -52.31% beat Proteostasis Therapeutics' return on equity.
Proteostasis Therapeutics received 279 more outperform votes than Spruce Biosciences when rated by MarketBeat users. However, 64.41% of users gave Spruce Biosciences an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote.
16.6% of Proteostasis Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 4.8% of Proteostasis Therapeutics shares are held by insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Spruce Biosciences has a consensus target price of $5.67, suggesting a potential upside of 664.11%. Given Spruce Biosciences' higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Proteostasis Therapeutics.
Spruce Biosciences has higher revenue and earnings than Proteostasis Therapeutics. Spruce Biosciences is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Spruce Biosciences beats Proteostasis Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Proteostasis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Proteostasis Therapeutics Competitors List
Related Companies and Tools
